Mimcina Tablet (Cinacalcet) | Used for Parathyroid and Calcium Imbalance Treatment
Mimcina Tablet (Cinacalcet) is a calcimimetic medicine used to treat secondary hyperparathyroidism and control high parathyroid hormone (PTH) levels, especially in patients with chronic kidney disease on dialysis. It helps regulate calcium and phosphorus balance in the body by increasing the sensitivity of the parathyroid gland, thereby reducing excess PTH secretion.
Product Overview
Mimcina Tablet is an advanced, systemically acting oral calcimimetic agent designed to precisely regulate mineral and bone metabolism. Containing the active pharmaceutical substance Cinacalcet Hydrochloride, this medication is engineered to treat secondary hyperparathyroidism in adult patients with chronic kidney disease (CKD) who are undergoing dialysis. It is also highly effective at managing severe hypercalcemia (abnormally high blood calcium levels) in patients diagnosed with primary hyperparathyroidism (who are unable to undergo surgery) or parathyroid carcinoma. By modifying how the body perceives circulating calcium, Mimcina helps normalize complex mineral imbalances, offering critical protection against progressive bone degradation and soft tissue calcification.
Product Composition
- Active Pharmaceutical Ingredient: Cinacalcet Hydrochloride (formulated standardly as a 30mg film-coated oral tablet)
- Dosage Form: Solid oral film-coated tablets, designed for consistent gastrointestinal absorption when paired with dietary lipids
- Core Excipients: Formulated within a stable matrix including microcrystalline cellulose, pre-gelatinized maize starch, crospovidone, talc, and magnesium stearate
Product Specification
| Product Parameter | Details |
| Brand Name | Mimcina Tablet |
| Active Ingredient | Cinacalcet Hydrochloride |
| Therapeutic Class | Calcium Homeostasis Agents / Calcimimetics |
| Available Strength | 30mg |
| Primary Indications | Management of secondary hyperparathyroidism in dialysis patients; reduction of hypercalcemia in parathyroid cancer or in inoperable primary hyperparathyroidism |
Mechanism of Action
- Allosteric Modulation of Calcium-Sensing Receptors: Cinacalcet functions as a positive allosteric modulator of the calcium-sensing receptors (CaSR) found abundantly on the chief cells of the parathyroid gland. It binds directly to the receptor, altering its shape to increase its sensitivity to extracellular calcium ions.
- Suppression of Parathyroid Hormone Secretion: By tricking the parathyroid glands into behaving as though blood calcium levels are higher than they actually are, the medication directly suppresses the production, synthesis, and systemic secretion of intact parathyroid hormone (iPTH).
- Reduction of Serum Mineral Products: The reduction in circulating iPTH halts excessive bone resorption, which in turn leads to a controlled, simultaneous reduction of both calcium and phosphorus levels in the bloodstream.
- Prevention of Hypercalcemic Complications: In malignant or primary hyperparathyroid states, the direct drop in circulating hormone levels curbs the over-absorption of bone minerals, stabilizing bone tissue architecture and mitigating the dangerous systemic risks of hypercalcemia.
Key Benefits
- Directly targets the root cause of secondary hyperparathyroidism by turning down hormone production at the glandular level, eliminating the need for invasive surgical glandular removal in many patients.
- Simultaneously lowers both serum calcium and serum phosphorus levels, avoiding the elevated calcium-phosphorus mineral product buildup that contributes to painful cardiovascular calcifications.
- Significantly lowers the clinical risk of progressive bone diseases, severe bone pain, osteitis fibrosa cystica, and metabolic bone fractures common in long-term dialysis patients.
- Provides a highly scalable, predictable oral maintenance framework that can be safely titrated up over time to achieve stable, baseline mineral homeostasis.
Precautions
Important Precautions for Mimcina Tablet (Cinacalcet)
Mimcina Tablet is a calcimimetic medicine used to control high parathyroid hormone (PTH) levels. It should be used carefully due to its strong effect on calcium balance in the body.
| Precaution Area | Details |
|---|---|
| Calcium Levels | May cause low blood calcium (hypocalcemia). |
| Kidney Disease | Commonly used in CKD patients; requires monitoring. |
| Seizure Risk | Severe hypocalcemia may increase seizure risk. |
| Heart Conditions | Low calcium can affect heart rhythm. |
| Liver Function | Use cautiously in hepatic impairment. |
| Pregnancy & Breastfeeding | Use only if clearly prescribed. |
| Children | Safety and dose must be strictly determined by a specialist. |
Important Safety Advice
- Take exactly as prescribed with regular monitoring
- Do not skip calcium level checks during treatment
- Report symptoms of low calcium immediately
- Take with food to reduce stomach upset
- Do not adjust dose without medical advice
When to Avoid Mimcina Tablet
- Known hypersensitivity to Cinacalcet
- Severe hypocalcemia (low calcium levels)
- Uncontrolled seizure disorders due to calcium imbalance
Monitoring Requirements
- Serum calcium levels (frequent monitoring)
- Parathyroid hormone (PTH) levels
- Phosphate levels in CKD patients
- ECG monitoring if needed for cardiac risk
General Note
- Requires strict laboratory monitoring throughout therapy
- Dose adjustments are common based on calcium response
- Always follow nephrologist or endocrinologist supervision carefully
Usage
This calcimimetic agent requires strict laboratory oversight and personalized dose adjustments. Because it directly alters serum mineral levels, treatment initiation and subsequent titration must be guided by frequent blood chemistry panels to maintain safety and efficacy.
| Parameter | Clinical Guidelines |
| Secondary Hyperparathyroidism Dosing | The recommended starting dose for adult patients is 30mg once daily. The dosage can be titrated every 2 to 4 weeks up to a maximum of 180mg once daily to achieve target parathyroid hormone levels. |
| Hypercalcemia Dosing | The typical starting dose for managing parathyroid cancer or primary hyperparathyroidism is 30mg twice daily, titrated gradually based on blood calcium reductions. |
| Administration Rule | Must be swallowed whole during or immediately after a meal. Food significantly enhances bioavailability and reduces potential gastrointestinal side effects. |
| Safety Monitoring | Serum calcium levels must be measured within 1 week after starting therapy or after any dose modification. Do not increase the dose if hypocalcemia (low calcium) is present. |
Uses
Treatment of Secondary Hyperparathyroidism: Indicated to reduce elevated parathyroid hormone levels in adult patients with chronic kidney disease who are undergoing maintenance dialysis therapy.
Management of Malignant Hypercalcemia: Prescribed to lower dangerously elevated serum calcium concentrations in patients diagnosed with parathyroid carcinoma.
Control of Inoperable Primary Hyperparathyroidism: Utilized to treat severe hypercalcemia in adult patients with primary hyperparathyroidism for whom surgical removal of the parathyroid glands is clinically inappropriate or impossible.
Prevention of Mineral Metathesis: Employed to regulate the circulating calcium-phosphorus mineral product, helping shield patients from severe vascular, cardiac, and soft-tissue calcification over long-term therapy.
Side Effects
Possible Side Effects of Mimcina Tablet (Cinacalcet)
Mimcina Tablet is a calcimimetic medicine used to control parathyroid hormone (PTH) levels. Side effects are mainly related to changes in calcium balance in the body.
| Side Effect Type | Details |
|---|---|
| Common Effects | Nausea, vomiting, loss of appetite. |
| Calcium Effects | Low blood calcium (hypocalcemia). |
| Nervous System | Dizziness, tingling sensation. |
| Muscle Effects | Muscle cramps, weakness. |
| General Effects | Fatigue, headache. |
| Severe Effects | Seizures, irregular heartbeat (rare, due to low calcium). |
Common Side Effects
- Nausea or vomiting
- Loss of appetite
- Headache
- Dizziness
Less Common But Important Effects
- Muscle cramps or tingling in hands/feet
- Fatigue or weakness
- Low calcium-related symptoms
- Abdominal discomfort
When to Be Careful
- Tingling around mouth or fingers
- Severe muscle cramps or spasms
- Irregular heartbeat or chest discomfort
- Seizures or severe weakness
General Note
- Most side effects are related to low calcium levels
- Regular blood tests are essential during treatment
- Dose adjustment helps reduce adverse effects
- Report symptoms of hypocalcemia immediately to a doctor
FAQs
Q: What is Mimcina Tablet used for?
A: This medication is an oral calcimimetic agent used to treat secondary hyperparathyroidism in adult patients with chronic kidney disease who are on dialysis. It is also used to lower high calcium levels in the blood (hypercalcemia) in patients with parathyroid cancer or those with primary hyperparathyroidism who cannot undergo surgery.
Q: How does Cinacalcet lower parathyroid hormone levels?
A: It works by increasing the sensitivity of the calcium-sensing receptors on the parathyroid glands. This tricks the glands into thinking there is more calcium in the blood than there actually is, which causes them to significantly cut back on the production and release of parathyroid hormone.
Q: Why must Mimcina Tablets be taken with food?
A: You should take this medication during or immediately after a meal. Clinical data shows that taking cinacalcet with food increases its absorption in the gastrointestinal tract, ensuring the medication works effectively while helping to minimize common stomach upsets.
Q: Can this medication cause blood calcium levels to drop too low?
A: Yes, hypocalcemia (low blood calcium) is a known risk. Signs of low calcium include numbness or a tingling sensation around the mouth, muscle aches, severe cramping, tremors, or seizures. If you experience any of these neurological or muscle symptoms, notify your medical team immediately.
Q: How often will I need blood tests while taking this medication?
A: Your doctor will monitor your blood work frequently. Serum calcium levels and phosphorus levels are typically checked within one week of starting or adjusting your dose. Once a stable maintenance dose is established, calcium levels are measured monthly, and parathyroid hormone levels are checked every 1 to 3 months.
Q: What are the most common side effects of Mimcina?
A: The most frequently reported side effects are gastrointestinal, including nausea and vomiting. Most cases are mild to moderate and temporary, but your healthcare provider can offer strategies or adjustments if these symptoms persist.
Q: Can I crush or chew the tablets if they are difficult to swallow?
A: No, the film-coated tablets must be swallowed whole. Do not divide, crush, or chew them, as this can alter the absorption rate of the drug and affect how much active medication enters your system at once.
Q: What should I do if I miss a dose of Mimcina?
A: If you miss a dose, take it as soon as you remember with food, provided it is not close to your next scheduled dose. If your next dose is due within a short time window, skip the missed dose entirely and resume your regular schedule. Never take a double dose to make up for a missed one.
Interactions
Drug Interactions of Mimcina Tablet (Cinacalcet)
Mimcina Tablet (Cinacalcet) may interact with medicines that affect calcium levels, heart rhythm, or liver enzymes. These interactions can increase the risk of hypocalcemia or alter drug effectiveness.
| Medicine or Product Type | Interaction Details |
|---|---|
| Calcium Supplements | May reduce effectiveness of Cinacalcet or mask hypocalcemia. |
| Vitamin D Preparations | Can affect calcium balance and treatment response. |
| Bisphosphonates | Additive effects on calcium reduction. |
| Antiepileptics | May alter seizure threshold if calcium becomes low. |
| Antiarrhythmic Drugs | Increased risk of heart rhythm abnormalities with low calcium. |
| CYP3A4 Inhibitors | May increase Cinacalcet levels in the body. |
| Strong CYP3A4 Inducers | May reduce effectiveness of Cinacalcet. |
Important Interaction Advice
- Regular calcium monitoring is essential when used with interacting drugs
- Inform doctor about all supplements and vitamin D intake
- Avoid self-medication with calcium or phosphate products
- Dose adjustments may be required in combination therapy
General Guidance
- Monitor for symptoms of low calcium (tingling, muscle cramps, weakness)
- ECG monitoring may be required in high-risk patients
- Always provide full medication history before starting treatment
- Use only under specialist supervision in CKD patients
Additional Note
- Cinacalcet significantly affects calcium regulation, so drug combinations must be carefully managed to avoid serious electrolyte imbalance and cardiac risks
| Manufacturer | : | Steadfast Medishield Pvt Ltd |
| Trade Name | : | Sensipar |
| Generic Search | : | Cinacalcet |
| Strength | : | 30mg |
Latest Products
